REGENERON PHARMACEUTICALS, INC. (REGN)

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Its core strategy centers on scientific research and drug development using proprietary technologies, complemented by clinical development, manufacturing, and commercial capabilities, with the goal of operating as an integrated, multi-product biotechnology company. The company's commercialized product portfolio includes EYLEA HD and EYLEA (aflibercept) for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and related retinal conditions, developed in collaboration with Bayer outside the United States; Dupixent (dupilumab), developed and commercialized with Sanofi, approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, COPD, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid; Libtayo (cemiplimab), a globally marketed oncology product for non-small cell lung cancer, basal cell carcinoma, cutaneous squamous cell carcinoma, and cervical cancer, on which Regeneron pays Sanofi a royalty; Praluent (alirocumab) for cardiovascular risk reduction and hypercholesterolemia, commercialized by Regeneron in the U.S. and by Sanofi outside the U.S.; Kevzara (sarilumab), developed with Sanofi for rheumatoid arthritis, polymyalgia rheumatica, and polyarticular juvenile idiopathic arthritis; Evkeeza (evinacumab) for homozygous familial hypercholesterolemia, commercialized by Regeneron in the U.S. and by Ultragenyx elsewhere; Ordspono (odronextamab) for follicular lymphoma and diffuse large B-cell lymphoma; Lynozyfic (linvoseltamab) for relapsed/refractory multiple myeloma; Inmazeb for Zaire ebolavirus infection; Veopoz (pozelimab) for CHAPLE disease; ARCALYST (rilonacept), commercialized by Kiniksa, for CAPS, DIRA, and recurrent pericarditis; and ZALTRAP (ziv-aflibercept), commercialized by Sanofi, for metastatic colorectal cancer.

The company generates revenue through direct product sales, collaboration revenue (including profit-sharing arrangements with partners such as Sanofi and Bayer), and royalty income, serving patients and healthcare providers across the United States, the European Union, Japan, and other international markets. For the year ended December 31, 2025, Regeneron reported total revenues of $14,342.9 million and net income of $4,504.9 million, with key products such as Dupixent generating $17,806.7 million in global net sales and EYLEA HD and EYLEA together generating $7,891.0 million, reflecting the company's reliance on a diversified, multi-product portfolio supported by strategic collaborations with major pharmaceutical partners.